rasagiline has been researched along with Disease Exacerbation in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (23.08) | 29.6817 |
| 2010's | 19 (73.08) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Archer, DB; Arpin, DJ; Burciu, RG; Chu, WT; Gao, H; Guttuso, T; Hess, CW; Lai, S; Malaty, IA; McFarland, NR; Mitchell, T; Okun, MS; Pasternak, O; Price, CC; Shukla, AW; Vaillancourt, DE; Wu, SS | 1 |
| Bhattacharya, SS; Calado, SM; Diaz-Corrales, FJ; Garcia-Delgado, AB; Valdés-Sánchez, L | 1 |
| Boentert, M; Dorst, J; Dreyhaupt, J; Dupuis, L; Emmer, A; Göricke, B; Grehl, T; Grosskreutz, J; Heneka, MT; Hermann, A; Kassubek, J; Ludolph, AC; Meyer, T; Petri, S; Prudlo, J; Schrank, B; Schuster, J; Weiland, U; Weishaupt, JH; Winkler, AS; Wollebæk Johannesen, S; Zeller, D | 1 |
| Abler, V; Goebel, G; Krismer, F; Papapetropoulos, S; Poewe, W; Schocke, M; Seppi, K; Wenning, GK | 1 |
| Chen, Y; Deng, L; Li, J; Qin, X; Sun, H; Tang, R; Yi, L; Zhang, C; Zhang, L; Zhang, Z; Zheng, J; Zhou, H | 1 |
| Stocchi, F | 1 |
| Biton, IE; Dror, V; Eliash, S; Rehavi, M | 1 |
| Bertotti, G; Boveri, N; Comi, C; Frazzitta, G; Ghilardi, MF; Maestri, R; Perini, M; Pezzoli, G; Riboldazzi, G; Turla, M; Uccellini, D | 1 |
| Müller, T | 1 |
| Eyal, E; Smith, KM; Weintraub, D | 1 |
| Hauser, RA; Lang, A; Poewe, W | 1 |
| Crispin, A; Hensler, M; Lorenzl, S; Nuebling, G; Paul, S; Zwergal, A | 1 |
| Brotchie, J; Fitzer-Attas, C | 1 |
| Armand, C; Cochran, J; François, C; Haycox, A; Murteira, S | 1 |
| Schwarzschild, MA | 1 |
| Ferreira, JJ; Sampaio, C | 1 |
| Chen, JJ | 1 |
| Fitzer-Attas, CJ; Goren, T; Hauser, RA; Hurtig, HI; Lew, MF; Ondo, WG; Wojcieszek, J | 1 |
| Armand, C; Groenendaal, H; Tarrants, ML | 1 |
| Bloem, BR; Boon, AJ; van Laar, T | 1 |
| Barker, RA; Evans, JR | 1 |
| Rascol, O | 1 |
| Schapira, AH | 1 |
| Coria, F; Cozar-Santiago, Mdel P | 1 |
| Freeman, JW; Matos, E; Simmons, M | 1 |
6 review(s) available for rasagiline and Disease Exacerbation
| Article | Year |
|---|---|
Pharmacokinetic/pharmacodynamic evaluation of rasagiline mesylate for Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Catechols; Disease Progression; Humans; Indans; Monoamine Oxidase Inhibitors; Nitriles; Oxidative Stress; Parkinson Disease; Selegiline | 2014 |
Mechanisms compensating for dopamine loss in early Parkinson disease.
Topics: Antiparkinson Agents; Corpus Striatum; Disease Progression; Dopamine; Globus Pallidus; Humans; Indans; Levodopa; Neural Pathways; Neurons; Parkinson Disease | 2009 |
Parkinson's disease: health-related quality of life, economic cost, and implications of early treatment.
Topics: Aged; Aged, 80 and over; Antiparkinson Agents; Disease Progression; Early Diagnosis; Health Care Costs; Humans; Indans; Middle Aged; Parkinson Disease; Quality of Life | 2010 |
Defining meaningful outcome measures in trials of disease-modifying therapies in Parkinson's disease.
Topics: Disease Progression; Endpoint Determination; Humans; Indans; Movement Disorders; Neuroprotective Agents; Parkinson Disease; Posture; Reflex, Abnormal; Research Design; Treatment Outcome | 2011 |
Present and future drug treatment for Parkinson's disease.
Topics: Benzothiazoles; Corpus Striatum; Disease Progression; Dopamine Agonists; Drug Therapy, Combination; Humans; Indans; Indoles; Levodopa; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Parkinson Disease; Pramipexole; Psychomotor Performance; Sexual Dysfunction, Physiological; Sleep Wake Disorders; Substantia Nigra; Thiazoles; Urinary Incontinence | 2005 |
Parkinson disease: an incremental challenge.
Topics: Catechols; Deep Brain Stimulation; Disease Progression; Humans; Indans; Nitriles; Parkinson Disease | 2007 |
11 trial(s) available for rasagiline and Disease Exacerbation
| Article | Year |
|---|---|
Diffusion Magnetic Resonance Imaging Detects Progression in Parkinson's Disease: A Placebo-Controlled Trial of Rasagiline.
Topics: Diffusion Magnetic Resonance Imaging; Disease Progression; Double-Blind Method; Humans; Indans; Parkinson Disease; Prospective Studies | 2022 |
Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Topics: Aged; Amyotrophic Lateral Sclerosis; Body Mass Index; Disease Progression; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Retrospective Studies; Riluzole; Treatment Outcome; Vital Capacity | 2018 |
Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy.
Topics: Aged; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Magnetic Resonance Imaging; Male; Middle Aged; Multiple System Atrophy; Neuroprotective Agents; Prospective Studies | 2019 |
Efficacy and safety of rasagiline as an adjunct to levodopa treatment in Chinese patients with Parkinson's disease: a randomized, double-blind, parallel-controlled, multi-centre trial.
Topics: Adult; Aged; Antiparkinson Agents; Asian People; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Humans; Indans; Levodopa; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease | 2013 |
Benefits of treatment with rasagiline for fatigue symptoms in patients with early Parkinson's disease.
Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Double-Blind Method; Fatigue; Female; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Treatment Outcome | 2014 |
Intensive rehabilitation treatment in early Parkinson's disease: a randomized pilot study with a 2-year follow-up.
Topics: Aged; Analysis of Variance; Antiparkinson Agents; Disease Progression; Exercise Therapy; Female; Follow-Up Studies; Humans; Indans; Male; Parkinson Disease; Pilot Projects; Severity of Illness Index; Treatment Outcome; Walking | 2015 |
Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents; Apathy; Depression; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Parkinson Disease; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep; Treatment Outcome; Wakefulness | 2015 |
Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
Topics: Activities of Daily Living; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
Topics: Aged; Area Under Curve; Cognition Disorders; Depression; Disease Progression; Double-Blind Method; Electrocardiography; Executive Function; Female; Follow-Up Studies; Humans; Indans; Male; Mental Status Schedule; Middle Aged; Monoamine Oxidase Inhibitors; Postural Balance; Sensation Disorders; Supranuclear Palsy, Progressive | 2016 |
Long-term efficacy of rasagiline in early Parkinson's disease.
Topics: Antiparkinson Agents; Cohort Studies; Disease Progression; Dopamine Agents; Dopamine Agonists; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; Humans; Indans; Kaplan-Meier Estimate; Levodopa; Middle Aged; Parkinson Disease; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease.
Topics: Activities of Daily Living; Aged; Antiparkinson Agents; Cohort Studies; Disability Evaluation; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Monoamine Oxidase Inhibitors; Parkinson Disease | 2004 |
9 other study(ies) available for rasagiline and Disease Exacerbation
| Article | Year |
|---|---|
Rasagiline delays retinal degeneration in a mouse model of retinitis pigmentosa via modulation of Bax/Bcl-2 expression.
Topics: Administration, Oral; Animals; Animals, Newborn; bcl-2-Associated X Protein; Disease Models, Animal; Disease Progression; Gene Expression; Indans; Mice, Transgenic; Neuroprotective Agents; Photoreceptor Cells; Proto-Oncogene Proteins c-bcl-2; Retina; Retinitis Pigmentosa; Vision, Ocular | 2018 |
Rasagiline prevents neurodegeneration in thiamine deficient rats-a longitudinal MRI study.
Topics: Animals; Brain; Diffusion Tensor Imaging; Disease Models, Animal; Disease Progression; Indans; Kaplan-Meier Estimate; Lateral Ventricles; Longitudinal Studies; Magnetic Resonance Imaging; Male; Monoamine Oxidase Inhibitors; Nerve Degeneration; Neuroprotective Agents; Organ Size; Pyrithiamine; Rats; Rats, Sprague-Dawley; Thalamus; Thiamine Deficiency | 2014 |
Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
Topics: Aged; Antiparkinson Agents; Benzothiazoles; Clinical Trials as Topic; Cost-Benefit Analysis; Disease Progression; Dopamine Agonists; Female; Health Care Costs; Humans; Indans; Insurance, Health, Reimbursement; Male; Markov Chains; Middle Aged; Models, Economic; Monoamine Oxidase Inhibitors; Monte Carlo Method; Parkinson Disease; Pramipexole; Probability; Quality-Adjusted Life Years; State Medicine; Treatment Outcome; United Kingdom | 2009 |
Rasagiline in Parkinson's disease.
Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Outcome Assessment, Health Care; Parkinson Disease; Research Design | 2010 |
Parkinson disease: ADAGIO trial hints that rasagiline slows disease progression.
Topics: Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Humans; Indans; Neuroprotective Agents; Parkinson Disease; Time Factors | 2010 |
Treatment of advanced Parkinson's disease in the United States: a cost-utility model.
Topics: Antiparkinson Agents; Carbidopa; Catechols; Cost Savings; Cost-Benefit Analysis; Disease Progression; Drug Administration Schedule; Drug Costs; Drug Therapy, Combination; Humans; Indans; Levodopa; Markov Chains; Models, Economic; Nitriles; Parkinson Disease; Quality of Life; Quality-Adjusted Life Years; Stochastic Processes; Time Factors; Treatment Outcome; United States | 2010 |
[Rasagiline is not for all Parkinson disease patients: the ADAGIO study].
Topics: Disease Progression; Dose-Response Relationship, Drug; Humans; Indans; Monoamine Oxidase Inhibitors; Parkinson Disease; Randomized Controlled Trials as Topic; Treatment Outcome | 2010 |
[Disease-modifying therapies in PD].
Topics: Animals; Disease Models, Animal; Disease Progression; Dopaminergic Neurons; Endpoint Determination; Humans; Indans; Parkinson Disease; Randomized Controlled Trials as Topic | 2010 |
Rasagiline improves freezing in a patient with primary progressive freezing gait.
Topics: Aged, 80 and over; Brain; Disease Progression; Gait Disorders, Neurologic; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Tomography, Emission-Computed, Single-Photon | 2008 |